Skip to main content

Table 2 Summary of clinical response.

From: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus

Patient number Clinical outcome Time to complete response (weeks) Follow-up period (months) Maximun dose received (mg) Relapse Dose at relapse
1 CR 10 15 5 Yes 5 mg twice weekly
2 CR 4 12 5 Yes 5 mg three times weekly
3 Withdrawn - - 5 - -
4 CR 3 12 5 Yes 5 mg alternate days
5 CR 36 19 5 - -
6 CR 4 17 5 No -
7 CR 11 18 5 No -
8 CR 2 7 5 Yes 5 mg alternate days
9 PR - 15 10 - -
10 CR 7 10 5 Yes 5 mg alternate days
11 CR 4 30 5 Yes 5 mg twice weekly
12 CR 4 25 5 Yes 5 mg alternate days
13 PR - 8 5 - -
14 CR 12 17 5 Yes 5 mg three times weekly
15 CR 2 10 5 Yes 5 mg alternate days
  1. CR, complete response; PR, partial response.